OVID THERAPEUTICS DL-,001

Ovid Therapeutics appointed Kevin Norrett as chief business officer to lead business development and strategic partnerships. Charles Carter was promoted to CFO, succeeding Jeffrey Rona who will remain a long-term advisor through 2027, and Victoria Fort was promoted to chief strategy officer. The company reported Q1 EPS of (12c), said development programs are on track, and expects to be well capitalized into 2029. » More on finance.yahoo.com

Ovid Therapeutics brings in Kevin Norrett as chief business officer to lead business and corporate development and strategic partnerships. Charles Carter was promoted to chief financial officer; Jeffrey Rona will remain on board as an advisor through 2027. Eliseo Salinas joins as executive R&D advisor and Victoria Fort was promoted to chief strategy officer; Fort led financing rounds that secure the company’s cash runway through 2029. The company is developing, among others, OV329 for treatment-resistant focal-onset seizures and OV4071 for central nervous system disorders. » More on de.investing.com

Ovid Therapeutics has appointed Dr. Anna Greka to its board effective June 15, 2026; she will chair the newly formed Science and Technology Committee and join the Compensation Committee. Dr. Greka is head of Ladders to Cures, a Core Institute member at the Broad Institute, a professor at Harvard Medical School, and has founded and advised several biotech companies. The announcement comes after the stock rose more than 700% over the past year; Ovid is developing, among other programs, OV329 for treatment-resistant focal onset seizures and additional KCC2 activators. » More on de.investing.com